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Mechanism of Nitrofen Teratogenesis
by Jeanne M. Manson*
Nitrofen (2,4-dichloro-4'-nitrodiphenyl ether) is an herbicide with potent teratogenic activity in rats.
When administered at doses as low as 0.15 mg/kg/day during organogenesis, abnormal development ofthe
heart, kidneys, diaphragm, and lung occurs. The specific pattern of visceral malformations produced in
the absence ofovert maternal toxicity or embryolethality/cytotoxicity suggest thatthe compound perturbs
processes unique or highly selective forembryonic differentiation. Despite findings ofmetabolic activation
to mutagenic intermediates and carcinogenic activity in adult rodents, several lines of evidence indicate
that teratogenicity is not based on mutagenic insult to the embryo. Rather, evidence is accumulating that
nitrofen exerts a teratogenic effect via alterations in thyroid hormone status. The premature and phar-
macologic exposure ofthe embryo to a nitrofen-derived thyromimetic challenge is believed to be the cause
of abnormal morphogenesis of the heart, lungs, kidneys, and diaphragm. The parent compound itself
could directly bind to embryonic nuclear receptors for T3, leading to altered differentiation of target
organs. Alternatively, increased availability and placental transport of free thyroid hormones in the
maternal compartment couldbe the source ofthyromimetic challengetotheembryo. Overall, these studies
indicate that, in the case ofnitrofen, the mode ofteratogenic activity is uniquely different from the mode
of adult toxicity.
Introduction
Previous speakers have presented findings on a va-
riety of agents well-established in laboratory animal
models as teratogens. This has permitted relatively di-
rect and extensive examination of mechanism and site
of action. In some cases, in vivo pharmacokinetic and
biotransformation have yielded information critical to
understanding teratogenic potency. In other cases, in
vitro approaches have provided the necessary isolation
ofembryonic tissues to gain insight into the cellular and
molecular mechanism of action. In this paper, I will
present findings from studies conducted in my labora-
tory on the teratogen, nitrofen. When we first began
studying this agent approximately six years ago, we
had very little information onits adult ordevelopmental
toxicity. Consequently, much effort went into first de-
fining the developmental toxicity in rodents, and then
into examining a number of parameters potentially re-
lated to mechanism of action. This was a multidiscipli-
nary process that included examination of the in vivo
response to the agent, its distribution and metabolism
in pregnant animals, and finally insight into the mech-
anism and site of action. The main intent ofthis paper
is to describe the approach we took in starting from the
beginning to define the developmental toxicity ofnitro-
fen. This will hopefully provide a comprehensive per-
spective on the multilayered approach required to un-
derstand the teratogenic properties of an individual
agent.
*Reproductive and Developmental Toxicology, Smith Kline and
French Laboratories, Philadelphia, PA 19101.
Background
Nitrofen (2,4-dichloro-4'-nitrodiphenyl ether) is a se-
lective contact herbicide used on a variety offood crops
for pre- and post-emergence control of annual grasses
and weeds. It is a member of the chlorophenoxy class
of herbicides and is also called nitrophene, TOK, TOK
E-25, and Nip (1). Food tolerance levels ranging from
0.02 to 0.75 ppm have been established for a number of
commodities including vegetables, milk, rice, poultry
and meats (2). Technical grade nitrofen contains ap-
proximately 95% active ingredient with impurities con-
sisting of approximately 3% p-chloronitrobenzene, 1%
dichlorophenol, and 1% unknown. Woolson et al. (3)
specifically determined that technical grade nitrofen
lacked 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) con-
taminants.
Nitrofen is spread on soil surfaces and is adsorbed
onto weeds as they emerge. The compound is activated
by sunlight and kills weeds by inhibiting photosyn-
thesis. Activation for herbicidal activity appears to in-
volve, but not be exclusively limited to, cleavage at the
ether linkage to form dichlorophenol and nitrophenol
(4). The biochemical mechanism ofherbicidal activity is
based upon interference with both oxidative and pho-
tosynthetic phosphorylation in mitochondria and chlo-
roplasts of plants. Nitrofen and other diphenyl ether
herbicides have been shown to inhibit chloroplast non-
cylic electron transport by removing or inactivating an
electron carrier associated with photosystem II ofpho-
tosynthesis, or the Hill reaction. Mitochondrial respi-
ration appears to be disrupted at several sites alongthe
electron transport chain (5).J. M. MANSON
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FIGURE 1. Postulated scheme of nitrofen metabolism in the rat with major metabolites depicted. Adapted from Brown and Manson (8).
Approximately 20 different metabolic species, includ-
ing intermediates and conjugates, have been identified
in adult rats after nitrofen exposure. Majormetabolites
include hydroxylation, nitroreduction and acetylation
products, all of which have intact ether linkages (Fig.
1) (6-8). The majority ofadministered compound is ex-
creted in the urine (23.6%) and feces (73.9%), with ap-
proximately 1% taken up by tissues. The postulated
route ofmetabolism in the rat consists ofnitroreduction
ofthe parent compound tothe 4'- amino derivative (me-
tabolite 3) which is formed in the GI tract and liverwith
oral exposure. The 4'-amino derivative is rapidly and
extensively conjugated to the 4'-acetylamine (metabo-
lite 4) which is retained at high levels in the liver and
fat. Alternatively, the 4'-amino derivative and intact
parent compound can be hydroxylated, resulting in me-
tabolites 1, 5, and 7.
Nitrofenis notacutelytoxicinlaboratoryanimals and
has oral LD50values rangingfrom 2.4 to 3.6g/kgin rats
and mice (1). In subehronic dietary toxicity studies,
dose-related increases in liver, testes and kidney
weights occurred at 500 ppmand higher. Elevated liver
weight and induction of cytochrome P-450 levels have
been consistent, early signs oflow-dose subchronic ex-
posure. In a cancer bioassay oftechnical grade nitrofen
mixed in the diet with 2% corn oil, pancreatic ductal
carcinoma was observed in female rats and hepatocel-
lular carcinoma in mice of both sexes (9). When the
bioassay was repeated (10), there was no positive as-
sociation between treatment and tumor-incidences in
rats of either sex. The incidences ofhepatocellular ad-
enomas and carcinomas in male and female mice, how-
ever, were statistically elevated at all treatment levels.
Based on results from these 2 studies, IARC (11) clas-
sified technical grade nitrofen as a carcinogen in exper-
imental animals.
Draper and Casida (12) have examined the mutage-
nicity of nitrofen in the Salmonella TA 100 strain with
metabolic activation. They found that reduction of the
-NO2 group on the parent compound is the principal
pathway of metabolism with rat liver S9 preparations
under anaerobic conditions. The metabolicreduction oc-
curred via formation of highly reactive nitroso (-NO)
and hydroxylamine (-NHOH) intermediates to form the
4'-amino (-NH2) metabolite. Under aerobic conditions
microsomal oxidation converted the amino (- NH2) to
the nitroso (-NO)intermediate. Theyconcludedthatthe
parent compound is a promutagen, and that the -NO,
-NHOH and -NH2 intermediates are mutagens in the
Ames assay with TA100. The -NO and -NHOH inter-
mediates were postulated to play a role in the carci-
nogenicity and teratogenicity of nitrofen.
Developmental Toxicology
The reproductive and developmental toxicity of ni-
trofen have been examined in over25 studies published
over the last 10 years (1). No adverse effects have been
observedonmaleorfemalefertilityorondevelopmental
process up to implantation. Exposure of pregnant ro-
dentsduringorganogenesis, however, hasuniformlyre-
sulted in severe developmental toxicity. When admin-
istered on days 8-18 of gestation to rats, newborns
lacking external malformations develop signs of respi-
ratory distress, become cyanotic and die shortly after
birth (13) (Table 1). Treatment on day 11 of gestation
(spermdayequaltoday 1)causedthegreatestreduction
in neonatal survival (7). When administered from 75-
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Table 1. Effect of nitrofen on neonatal survival when administered on days 8-18 of gestation.a
Treatment, mg/kg/ Relative maternal Percent survival to
day No. of litters wt gain, % Birth wt, g 1 hr 24 hr 25 days
Corn oil 5 18 6.3 ± 0.2 98 98 98
20 5 18 6.3 ± 0.1 95 93 92
31.2 5 13 5.8 ± 0.1* 43 42 0
50 5 14 5.6±0.1* 41 29 7
aNitrofen was administered orally as a solution in corn oil on days 8-18 of gestation to Sprague-Dawley rats. Adapted from Stone and
Manson (13).
*p < 0.05.
Table 2. Prenatal toxicity of nitrofen exposure.a
% Increase % Implants,
in maternal dead/ No. of live Fetal body
Dose, mg/kg wt, day 1-21 resorbed fetuses wt, g
0 37 3.7 13.4 5.63
75 39 3.1 12.6 5.46
150 40 3.5 11.0 5.49
250 35 4.1 10.8 5.37
400 31 5.8 10.4 4.70*
a Nitrofen was administered by gavage on day 11 ofgestation and
uterine contents examined on day 21. Adapted from Costlow and
Manson (7).
*p<0.05 (13).
Table 3. Visceral malformations induced by prenatal nitrofen
exposure'
% live fetuses with
Dose, Diaphragmatic Heart Any visceral
mg/kg hernias Hydronephrosis anomalies malformation
0 0 0 0 0
75 2 22 26 45
150 10 41 38 83
250 20 48 53 96
400 21 62 88 100
aConditions given in Table 2.
400 mg/kg on day 11, no adverse effects on maternal
weightgain, postimplantation survival ornumberoflive
fetuses at term were obtained, although fetal weight
was significantly depressed at the highest dose (Table
2). Skeletal and visceral examination of term fetuses
exposed on day 11 revealed dose-related increases in
major malformations of the heart, kidneys and dia-
phragm (Table 3) aswell aslunghypoplasia. Anunusual
aspect ofthese findings was that the compound induced
a specific pattern ofvisceral malformations alone with-
out causing decreased maternalweightgain, embryole-
thality or excess cell death in embryonic target organs
(14). Skeletal malformations were not observed, even
though embryonic limb buds in particular are highly
susceptible to teratogenic insult on day 11 of rat ges-
tation. Litter sizes at term were within normal ranges,
even at exposure levels that malform the entire litter,
indicating that most affected embryos survive to term
carryingmalformations. Thesefindingsindicate that ni-
trofen exerts ateratogeniceffectthroughspecificmech-
anism(s) ofaction most likely involving pertubations of
processes unique or highly selective for embryonic dif-
ferentiation.
Reviews of the literature on the teratogenic prop-
erties of nitrofen have revealed some discrepancies in
the pattern of major malformations produced with ex-
posure of different rat strains during organogenesis.
Kang et al. (15) recently compared the response ofdif-
ferent strains of rats [Long-Evans Hooded (LEH),
Sprague-Dawley (SD), and "virus antibody negative"
Sprague-Dawley (VAN-SD)] to oral exposure of nitro-
fen at 0, 6.25, 12.50, or 25 mg/kg/day on days 6-15 of
gestation. Abnormalities of the lung (hypoplasia), kid-
neys (hydronephrosis), diaphragm (hernia), and heart
(aorticarchanomalies, ventricularseptaldefects, trans-
positions ofgreat vessels) were observed in live fetuses
atterm. The incidence offetuses with anymalformation
was nearly identical across dose level for each strain of
rat (Fig. 2). There were, however, substantial differ-
ences in the pattern of malformations produced within
each strain (Fig. 3). The SD and VAN-SD rats re-
sponded similarly for all malformations but had signif-
icantly higher incidences ofdiaphragm and lung anom-
alies than LEH rats. Conversely, LEH rats had
significantly elevated levels of kidney anomalies com-
pared to SD and VAN-SD rats. The frequency ofheart
malformations was generally low and similar across
strains at the dose levels employed. These results sug-
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FIGURE 2. Incidence offetuses with any malformations in different
rat strains. Adapted from Kang et al. (15).
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FIGURE 3. Comparison of the malformation pattern produced within each rat strain. Adapted from Kang et al. (15).
gest that while the potency (total percentage of mal-
formed fetuses) ofnitrofen is similar in different strains
of rats, there are marked strain differences in embry-
onic target organs affected. This more likely due to
genetic differences in embryonic susceptibility than to
pharmacokinetics insofar as the potency ofnitrofen was
similar across rat strains. Results from this study also
suggest that lunghypoplasia and diaphragmatic hernias
share a common etiology in that they were found to-
gether in most fetuses examined from all strains.
A review of the published literature on the devel-
opmental toxicity ofnitrofen (16) has identified a LOEL
(lowest-observable-effect level) of 0.15 mg/kg/day for
production of malformations with oral treatment on
days 7-15 of gestation in the rat. Comparison of this
value to oral LD50 values of 2.4 to 3.6 g/kg in rats in-
dicates that the compound is a potent and selective te-
ratogen in rodents. This raises concern about the ter-
atogenicity of other diphenyl ethers, which constitute
a major class of pre- and post-emergent herbicides that
also includes bifenox, acifluoren, oxyfluorfen, CNP and
other candidates. Diphenyl ethers are also being used
industrially as components of heat transfer media, sol-
vents, and plasticizers (17).
abolic species reaching the embryonic compartment
(8,18). Following a single oral administration of radio-
labeled nitrofen on day 10 of rat gestation (sperm day
= day 0), maternal and embryonic tissues were col-
lected at intervals from 1.5 to 72 hr (Fig. 4). Radioac-
tivity was preferentially accumulated and retained in
maternal fat for over 72 hr. Peak levels were reached
in other maternal organs at 3-12 hr. The half-life for
total radioactivity in maternal plasma was estimated to
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Nitrofen in Pregnant Rats
The distribution and metabolism ofnitrofenhavebeen
examined in pregnant rats to obtain information on met-
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FIGURE 4. Radiolabeled nitrofen was administered on day 10 ofrat
gestation and maternal and embryonic tissues collected at the
indicated time intervals. Adapted from Brown and Manson (8).
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be 42 hr. Radioactivity was first detected in the em-
bryonic compartment at 3 hr, and continued to increase
to peak levels at 72 hr. Despite the accumulation of
radioactivity in the embryo over time, the actual levels
found in the embryonic compartment were low, and
comprised only 1% of the total 72 hr area under the
curve (Table 4).
HPLC analysis of maternal tissues and the embryo/
placental complex was carried out to characterize the
chemicalidentity oftheradiolabeled material. Afterini-
tial uptake in maternal tissues (Fig. 5), the parent com-
pound preferentially accumulated in maternal fat start-
ing at 12 hr. After 48 hr, there was a redistribution of
parent compound from fat to other maternal organs and
the embryonic compartment. The half-life of parent
compound in maternal plasma was 68 hr. The 5-hydroxy
derivative (see Fig. 1) was the major metabolite found
Table 4. Distribution of '4C-nitrofen in pregnant rats after oral
exposures on day 10 of gestation.a
Tissue concentration, dprn/mg tissue x 10-4
Time, hr Liver Heart Plasma Fat Embryo
1.5 8.2 1.8 0.6 9.3
3.0 8.6 3.0 1.4 25.9 0.08
6.0 7.9 3.4 1.5 54.4 0.07
9.0 6.9 4.3 1.5 50.6 0.09
12.0 7.2 2.9 1.5 79.6 0.13
24.0 4.3 2.3 1.6 116.8 0.14
48.0 3.1 1.6 1.0 98.7 0.32
72.0 2.7 1.8 0.6 109.3 0.27
72 HrAUC x 31.3 15.7 8.3 67.4 1.5
10-5
(Relative % of (25%) (13%) (7%) (54%) (1%)
total)
a The area under the curve (AUC) for each tissue in Figure 5 was
calculated to estimate partitioning of total radioactivity in maternal
and embryonic tissues. Adapted from Brown and Manson (8).
in maternal tissues, while the 4'-amino and 4'-acetyl-
amine derivatives were found at lower levels and all
exhibited single phase kinetics (data not shown). The
parent compound alone was found in the embryo from
1.5 to 72 hr after maternal exposure (limit ofdetection
0.03 ,ug/injection), and levels gradually increased as ni-
trofen redistributed from maternal fat at 48 hr after
exposure.
Despite previousfindings ofnitroreductionofnitrofen
to mutagenic intermediates in vitro (12), there are sev-
eral lines ofevidence suggestingthat the teratogenicity
ofnitrofen is not based metabolism to mutagenic inter-
mediates which reach the embryo. One is that Costlow
and Manson (18) administered the 4'-amino metabolite
at doses of 65 to 215 mg/kg on day 10 ofrat gestation.
This metabolite did not influence birth weight, pup
weight or neonatal survival to 5 days after birth, pa-
rameters which were severely affected by exposure to
equivalent doses ofthe parent compound. HPLC analy-
sis of tissues 6 hr after exposure detected only the 4'-
acetylamine, suggesting that the 4'-amino metabolite is
preferentially conjugated in vivo and not oxidized back
through the nitroso pathway.
In addition, Francis (17) examined the prenatal tox-
icity of nitrofen and 5 analogous diphenyl ether com-
pounds with different levels of chlorination. 2,4,5-Tri-
chlorophenyl-4'-nitrodiphenyl ethercausedsignificantly
more prenatal toxicity than nitrofen, while 2,4,6-tri-
chlorophenyl-4'-nitrophenyl ether was inactive. Like-
wise, monochlorinated and unchlorinated derivatives of
nitrofenhadnoadverse effects. Theseresultsimplythat
it is the number and position of chlorine groups on the
molecule and not the nitro group that determines ter-
atogenic activity.
In the present study (8), the 4'-amino derivative was
primarily found in the liver and appeared to be rapidly
Nitrofen (2,4-dichloro-4Laminodiphenyl ether)
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FIGURE 5. Distribution of parent compound in maternal and embryonic tissues. Adapted from Brown and Manson (8).
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conjugated to the 4'-acetylamine which reached rela-
tively high levels in the liver and fat. The absence of
both nitroreduction products in the embryonic com-
partment as well as the prevalence of the 5-hydroxy
metabolite inmaternaltissue suggestthatthemetabolic
profile in vivo may be substantially different than in-
dicatedfrom S9preparationsinvitro. Monooxygenation
reactions toformthe 5-hydroxyderivativeofthe parent
compound appear to be more prevalent with in vivo
metabolism. The present results do not discount the
possibility that mutagenic intermediates derived from
nitroreduction are formed in maternal tissues. The ab-
sence ofthe stable endpoint ofthe nitroreduction path-
way, the 4'-amino metabolite, in embryonic tissue sug-
gests that this metabolic pathway may not be relevant
to teratogenic induction.
Thyromimetic Mode of Action
Several levels ofevidence indicate that nitrofen may
exert ateratogenic effect via alterations in thyroid hor-
mone status. One is that nitrofen, as a diphenyl ether
compound, has astereochemical configuration similarto
thyroid hormone (Fig. 6). Both possess diphenyl ether
ring structures in which the aromatic rings are inclined
at an angle of 1200 and the planes ofthe aromatic rings
are perpendicular to each other. Manson et al. (19) ex-
amined the influence of nitrofen exposure on hypotha-
lamic-pituitary-thyroid function in nonpregnant, preg-
nant, and fetal rats and attempted to relate alterations
in thyroid hormone status to teratogenicity. In adult
thyroparathyroidectomized (TPTX) female rats, nitro-
fen exposure at 15 and 30 mg/kg/day for 2 weeks re-
sulted in significant suppression in thyroid stimulating
hormone (TSH) levels (Table 5). When a single dose of
250mg/kgwasadministered toeuthyroidrats, adepres-
sion in the release ofTSH after athyrotropin-releasing
hormone (TRH) challenge was observed (data not
Table 5. Thyroid hormone levels in female rats after nitrofen
exposure for two weeks.'
Group T4, mg/100 mL T3, mg/mL TSH, mg/mL
Sham 5.10 0.47 125
TPTX 2.02 0.10 1906
TPTX-15N 2.11 0.15 1173*
TPTX-30N 1.97 0.14 1318*
a Female rats were sham operated or thyroparathyroidectomized
(TPTX) and treated with 15 or 30 mg/kg/day ofnitrofen for 2 weeks.
Adapted from Manson et al. (19).
* p<0.05.
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shown). Pregnant euthyroid rats given a single dose of
250 mg/kg on day 11 had significantly depressed TSH
and T4 levels, and fetal T4 levels were markedly de-
pressed at term (Fig. 7). Coadministration of T4 with
nitrofen to TPTX pregnant rats resulted in a 70% re-
duction the frequency of malformed fetuses compared
with nitrofen exposure alone (Table 6). Heart malfor-
mations, in particular, were prevented by coadminis-
tration of nitrofen with T4. These results were inter-
preted to indicate that nitrofen teratogenicity is
mediated, at least in part, by alterations in maternal
and/orfetalthyroidhormone status. The premature and
pharmacological exposure of the embryo to a nitrofen-
derived thyromimetic substance may alter differentia-
tion of the heart, lungs, kidney and diaphragm.
This hypothesis has been pursued in a number ofav-
enues to identify the active agent and the primary site
of action. Competitive displacement studies in RIA's
for T4 and T3 indicated that a nitrofen metabolite (4-
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Table 6. Protection against nitrofen teratogenicity by thyroxine.'
Sham TPTX TPTX-T4 TPTX-N TPTX-N-T4
No. of litters examined 6 8 5 11 7
No. offetuses examined 67 76 39 125 73
% Litters with
Heart anomalies 0 0 0 100 29
Kidney anomalies 0 12 0 73 57
Diaphragm anomalies 0 0 0 27 29
X, % fetuses with
Heart anomalies (total) 0 0 0 26.7 ± 2.8 2.4 ± 1.6*
Aortic arch anomalies 0 0 0 12.4 ± 2.7 2.4 ± 1.6
Tetralogy of fallot 0 0 0 4.8 ± 2.9 1.3 ± 1.3
Ventricular septal defect 0 0 0 10.3 ± 3.7 0
Truncus arteriosus communis 0 0 0 1.6 ± 1.6 0
Kidney anomalies 0 3.1 ± 3.1 0 17.0 ± 4.0 8.6 ± 3.3
Diaphragmatic hernias 0 0 0 4.6 ± 2.4 3.1 ± 2.1
Total anomalies, % 0 3.1 ± 3.1 0 39.9 ± 5.3 12.3 ± 3.9*
'Rats were sham- or TPTX-operated on day 2 of pregnancy. Thyroid hormone was replaced (TPTX-T4) for the remainder of pregnancy;
nitrofen was administered at 25 mg/kg/day on days 9-11 ofpregnancy (TPTX-25N); or both nitrofen and T4 were given together (TPTX-25N-
T4) under the same conditions. Adapted from Manson et al. (19).
*p < 0.05
hydroxy-2,5-dichloro-4'-amino diphenyl ether, metab-
olite 1) competed with 1251-T3 for antibody binding,
while the parent compound and remainder of metabo-
lites failed to compete with 125I-T4 or 125I-T3 for anti-
body binding. The degree of crossreactivity of metab-
olite 1 was relatively low (0.88% relative to T3) and the
antibodies were directed against the 4-hydroxy region
ofthe molecule. Insofar as metabolite 1 is found at very
low levels in maternal tissues and has not beendetected
in the embryonic compartment, the significance of this
finding is questionable (19).
A series ofinvitro studies have recently been carried
out in which the competition ofnitrofen and metabolites
withT4forbindingtoratthyroidbindingglobulin(TBG)
was examined (20). Rat TBG was isolated from serum
by affinity chromatography followed by size exclusion
chromatography. A single protein capable ofspecific T4
binding with a molecular weight of52,700 was isolated.
These characteristics are similar to those previously
reported for transthyretin, or prealbumin, the major
thyroid hormone transport protein in the rat (21). Ni-
trofen and several metabolites were found to signifi-
cantly compete with 125I-T4 forbinding to rat TBG (Ta-
ble 7). Chlorination at the 2,4 position is likely to play
some role in this competition insofar as 2,4-dichlorodi-
Table 7. Competition of nitrofen and metabolites with T4 for rat
TBG binding.'
% relative competition
Compound IC50, mM l>I-T4
T4 0.009 100
Metabolite 7 0.021 42
Metabolite 4 0.031 29
Nitrofen 0.037 27
Metabolite 5 0.155 6
Metabolite 3 - 0
a Rat thyroid binding globulin (TBG), or prealbumin, was isolated
from serum and competition between nitrofen and metabolites with
1`I-T4 for binding was determined. Adapted from Brown et al. (20).
phenyldichloroethane (o,p'-DDD) and 2,4-dinitrophenol
are known to have the same effect (22). The fact that
metabolite 3 (2,4-dichloro-4'-aminodiphenyl ether) did
notcompete, however, indicatesthatothersubstituents
or stereochemical configurations also play a role.
The competition of nitrofen and several metabolites
withT4 forratTBG bindingdoes explainat leastin part
some of the perturbations in thyroid hormone status
seen in the maternal compartment. Consequences of
this competition are that increased levels of free T4
would be available for conversion to free T3. Elevated
free T4 and T3 would then negatively feed back to the
pituitary and decrease maternal TSH release, as has
been identified (Fig. 7). Also, the level oftotal T4 would
decrease insofar as over 98% ofcirculatingT4 is protein
bound, a finding also previously identified in pregnant
rats treated with nitrofen (Fig. 7). Overall, there would
be higher levels of free thyroid hormone available for
exerting a physiological effect in the maternal com-
partment and also potentially available for transport
across the placenta to the embryonic compartment.
The thyromimetic activity of nitrofen was further
evaluated by examining biochemical indicators of thy-
roid hormone exposure in maternal and fetal tissues
after nitrofen treatment at 0, 12.5, 25, and 50 mg/kg!
day on days 6-15 of gestation in the rat (23). Serum
levels ofT4 and T3 were measured on days 15 through
21 in the dam and on days 19 and 21 in the fetus. Malic
enzyme activity and total phospholipid content (surfac-
tant) were also measured in fetal lung as indicators of
a thyromimetic challenge to the fetus.
Maternal T4 levels were initially depressed, as pre-
viously reported, but then increased to exceed control
values in an apparent negative feedback at term (data
notshown). MaternalserumT3levelsweresignificantly
elevated in all treatment groups on days 17-21 of ges-
tation (Fig. 8). Fetal serum T4 levels were significantly
decreased in a dose-dependent manner on days 19 and
21 (Fig. 9, day 21 alone). Serum T3 was barely detect-
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FIGURE 8. Maternal serum T3 levels after nitrofen treatment on
days 6-15 of pregnancy. Adapted from Tellone and Manson (23).
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FIGURE 9. Fetal serum T4 levels after nitrofen treatment on days
6-15 of pregnancy. Adapted from Tellone and Manson (23).
able in control fetuses on day 19; pooled fetal samples
from three of five control litters had measurable levels
with a mean of0.05 ng/mL, a level below the valid limit
of detection of the assay (0.1 ng/mL) (Fig. 10). Serum
from fetuses exposed to nitrofen had barely perceptible
increases in T3 levels up to 0.13 ng/mL in the high-dose
group on day 19. By day 21, control values for fetal
serum T3 were at the limit of detection and slight ele-
vations were observed in fetuses from the two highest
dose groups. HPLC analysis indicated that parent com-
pound and traces ofmetabolite 7 alone (2,4-dichloro-3'-
hydroxy-4'-nitrodiphenyl ether) were present in ma-
ternal and fetal seraatthese timepoints. Consequently,
the elevations in maternal and fetal serum T3 levels
Day 19
T
o.io
Day 21
T
o 50.0 0
mg/kg Nitrofen
0.05 S
0.001 0
FIGURE 10. Fetal serum T3 levels after nitrofen treatment on days
6-15 of pregnancy. Adapted from Tellone and Manson (23).
Table 8. Relative fetal lung weight.'
Nitrofen Relative fetal lung weight
exposure, mg/
kg Day 15 Day 17 Day 19 Day21
Control 1.28 2.68 3.49 2.81
(0.08) (0.11) (0.04) (0.13)
12.5 1.10 2.54* 3.19* 2.28t
(0.09) (0.07) (0.32) (0.14)
25.0 1.15 2.46* 3.10* 2.21t
(0.09) (0.11) (0.14) (0.08)
50.0 1.10 2.28t 2.96t 2.09t
(0.04) (0.21) (0.11) (0.07)
a Relative fetal lung weight after nitrofen exposure on days 6-15
ofgestation. Adapted from Tellone and Manson (23).
* p<0.05.
t p<0.01.
were not due to the presence of metabolite 1, which
crossreacts with antibodies forT3 and were presumably
due to the presence of endogenous T3.
Relative lung weights from nitrofen-treated fetuses
in this experiment were significantly depressed from
day 17 to day 21 ofgestation (Table 8). Total lungphos-
pholipids were measured as an estimate of fetal lung
surfactant content. On day 15, phospholipid levels in
pooled lungs from control litters were not measurable
(Table 9). Intreated lungsthere was anincreaseinboth
the frequency ofpositive litters and inthe level ofphos-
pholipid. Slight increases were seen on days 17 and 19
of gestation in treated lungs, and by day 21 no differ-
ences in phospholipid levels were evident although
treated lungs were markedly smaller than the controls.
A similar trend was observed with malic enzyme activ-
ity in fetal lungs (Table 10). A dose-related increase in
malic enzyme activity was found intreatedlungs onday
19 of gestation which was no longer apparent by day
21.
The interpretation of these results is that nitrofen
-
-
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Table 9. Fetal lung phospholipids-day 15.a
Phospholipids, ,ug P/mg protein
Litter no. Control 12.5 mg/kg 25.0 mg/kg 50.0 mg/kg
1 0.00 0.00 5.32 7.03
2 0.00 0.00 0.00 4.87
3 0.00 7.20 6.82 7.39
4 0.00 0.00 0.00 0.00
5 0.00 2.41 0.00 0.00
Mean (SEM) 0.00 1.92 2.43 3.86
(0.00) (1.40) (1.51) (1.63)
Mean (SEM) 0.00 4.81 6.07* 6.43*
(Excluding (0.00) (2.40) (0.75) (0.79)
Zeros)
a Total phospholipid levels in fetal lungs after nitrofen treatment
on days 6-15 of pregnancy. Adapted from Tellone and Manson (23).
* p<0.01.
Table 10. Malic enzyme activity in fetal lung.a
Malic enzyme activity, ,umole/min/mg protein
Day 19 Day 21
Control
Mean + SEM 5.01 ± 0.46 8.41 ± 0.95
12.5 mg/kg
Mean ± SEM 6.18 ± 0.71 8.72 ± 1.12
25.0 mg/kg
Mean ± SEM 6.21 ± 0.15 8.21 ± 0.84
50.0 mg/kg
Mean ± SEM 6.99 ± 0.91* 7.76 ± 1.72
a Malic enzyme activity in fetal lungs after nitrofen treatment on
days 6-15 ofpregnancy. Adapted from Tellone and Manson (23).
* p<0.05.
exposure resulted in a thyromimetic challenge to the
conceptus. In the case of the fetal lung, this was man-
ifested as a transient stimulation oflung differentiation
at the expense oflung growth. This concept is identical
to that developed for explanation of thyroid hormone
action on differentiation ofthe central nervous system.
Thyroid hormone alters the course of development in
neural tissues by inhibiting proliferation and stimulat-
ing differentiation (24). This concept could also be ex-
trapolated to provide an explanation for the heart mal-
formations produced by nitrofen exposure. The
resultant thyromimetic challenge could cause a preco-
cious appearance or increase in density of ,-adrenergic
receptors in the embryonic heart, as has been-demon-
strated in neonatal and adult tissue (25). Heart malfor-
mations, particularly ofthe arterial outflow tract, have
been produced in embryonic chicks via 13-adrenergic
stimulation, presumablythrough altered cardiovascular
hemodynamics (26). No link can yet be made between
a thyromimetic challenge and kidney and diaphragm
malformations. In general, little is known about the
mechanisms whereby teratogens alter the differentia-
tion of these tissues.
Current efforts are directed toward understanding
whatconstitutes thethyromimetic challengetothefetus
with nitrofen exposure. It has been conventionally held
that thyroid hormone is not important in rodent devel-
opment until the late fetal and postnatal period. This is
based on findings that the fetal thyroid gland does not
begin to synthesize and release thyroid hormone until
day 18 of gestation, and that the placenta is imperme-
able to transfer ofthyroid hormone. Consequently, de-
velopment is believed to occur in a thyroid hormone-
free environment until the fetal thyroid is functional
(27). These findings have recently been challenged by
findings that both T4 and T3 cross the placenta in sig-
nificant amounts during organogenesis in the rat.
Higher levels ofthese hormones were found in embryo
trophoblasts on days 10-12 ofgestation than in the con-
ceptusfrom days 13-18. Afterday 18, levelsweremark-
edly increased from fetal thyroid gland production (28).
Likewise, maternal thyroidectomy or iodine deficiency
caused a decrease in thyroid hormone levels in the con-
ceptus both before and after onset of fetal thyroid se-
cretion (29). Perez-Castillo et al. (30) have recently
shown that nuclear receptors for T3 were present as
early as day 13 of gestation in whole rat embryo ho-
mogenates. The receptor could be measured in individ-
ual organs from day 14 (brain) or day 16 (heart, liver,
and lung) onward. The presence ofboth T4 and T3, pre-
sumably from maternal origin, as well as the nuclear
receptor for T3 suggest that thyroid hormones could
influence development from day 13 onward.
With this recent evidence on the presence ofthyroid
hormone and its nuclear receptor during late organo-
genesis, there are at least two possible explanations for
the thyromimetic challenge that occurs with nitrofen
exposureto produce abnormal development. Oneisthat
the parent compound itself, or less likely a metabolites,
directly interacts with nuclear receptors for T3 in the
embryo. Precocious differentiation of those tissues ca-
pable of responding to thyroid hormone (lung, heart)
would occur and lead to abnormal morphogenesis.
Anotherexplanation is that primary effect ofnitrofen
is to cause alterations in maternal thyroid hormone sta-
tus, possibly due to competition with T4 for rat TBG
binding. Elevated levelsoffreethyroid hormoneswould
be available to cross the placenta, and maternally de-
rived hormones would constitute thethyromimeticchal-
lenge to the conceptus. This hypothesis is supported by
findings that the same pattern of depressed T4 and el-
evated T3 in the maternal compartment is also found in
the fetal compartment after nitrofen exposure on day
6-15 ofgestation. These two possibilities are nowbeing
explored by examining competition ofnitrofen and me-
tabolites with T3 for nuclearreceptor occupancy as well
as by monitoring levels ofthyroid hormone in the em-
bryonic compartment afterinvivo exposure tonitrofen.
Conclusions
Nitrofen is a potent teratogen in rats that produces
abnormal development of the heart, kidneys, dia-
phragm, and lung when administered during organo-
genesis. The specific pattern of visceral malformations
that occur in the absence of overt maternal toxicity or
embryolethality/cytotoxicity suggest that the com-
pound perturbs processes unique orhighly selective for
embryonic differentiation. Despitefindings ofmetabolic
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activation of nitrofen to mutagenic intermediates, sev-
eral lines ofevidence indicate that teratogenicity is not
based on mutagenic insult to the embryo. Rather, evi-
dence is accumulating that nitrofen exerts ateratogenic
effect via alterations in thyroid hormone status. The
premature andpharmacological exposure ofthe embryo
to a nitrofen-derived thyromimetic substance is be-
lieved to be the cause ofabnormalmorphogenesis ofthe
heart, lungs, kidneys, and diaphragm. The proximate
teratogen could be the parent compound itself which
directly binds to embryonic nuclear receptors for T3,
leading to altered differentiation of target organs. Al-
ternatively, increased availability and placental trans-
port of maternal thyroid hormones could be the proxi-
mate source of the thyromimetic challenge to the
embryo.
An important perspective to be gained from these
studies is that the developmental toxicity of an agent
can be considerably different and more complex than
itsadulttoxicity. Inthecaseofnitrofen, itscarcinogenic
activity can be explained by metabolism to mutagenic
intermediates. Its developmental toxicity, however, is
most likely based on an entirely different mechanism of
action involving a thyromimetic challenge to the con-
ceptus. Factors contributing to the specialty of devel-
opmental toxicity are the complex interactions that oc-
curbetweenmaternal, placentalandembryonicsystems
and the unique susceptibility ofembryonictissues. Con-
sequently, assumptions cannot be made that the mode
of developmental toxicity is identical to the mode of
adult toxicity, even for agents whose adult toxicity has
been well defined.
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